期刊文献+

阿卡波糖联合沙格列汀治疗不耐受二甲双胍的疗效观察 被引量:3

原文传递
导出
摘要 选取在门诊就诊的血糖不达标的、不耐受二甲双胍且超重的2型糖尿病患者62例,给予阿卡波糖联合沙格列汀治疗12周,监测患者治疗前后体重、体重指数、腹围、血压变化及血糖、糖化血红蛋白、胰岛素、血脂指标、胰岛素抵抗指数等指标的变化,并进行前后对照分析。结果经过联合治疗后,患者体重、体重指数、血压水平、胰岛素抵抗指数、总胆固醇、空腹胰岛素水平较前有所下降,高密度脂蛋白胆固醇较前有所上升,但差异无统计学意义(P>0.05);治疗后糖化血红蛋白、甘油三酯、低密度脂蛋白胆固醇、空腹血糖、早餐后2小时血糖及胰岛素水平较前下降,差异具有统计学意义(P<0.05);联合治疗期间无明确低血糖事件及其它不良事件发生。结论对于不耐受二甲双胍的超重2型糖尿病患者,阿卡波糖联合沙格列汀治疗安全有效,而且对血压、血脂等代谢指标也有改善作用。
出处 《实用糖尿病杂志》 2013年第3期14-15,共2页 Journal of Practical Diabetology
  • 相关文献

参考文献6

  • 1Yang WY, Lu JM, Weng JP, et al. Prevalence of Diabetes a- mong Men and Women in China. N Engl J Med 2010; 362 ( 12 ) : 1090 - 1101.
  • 2中华医学会糖尿病学分会.中国2型糖尿病防治指南[J].中华内分泌代谢杂志,2011,27(12):s12b1-s12b36.
  • 3Drouin P, Blickle JF,Charbonnel B, et al. Diagnosis and classi- fication of diabetes mellitus:the new criteria. Diabetes Metab 1999; 25:72 - 83.
  • 4American Diabetes Association, Standards of Medical Care in Diabetes-2013. Diabetes care 2012 ;36 ( S1 ) :21 - 25.
  • 5DeFronzo RA, Rather RE, Han J, et al. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in met- formin-treated patients with type 2 diabetes. Diabetes Care 2005 ;28 : 1092 - 1100.
  • 6Bolen S, Feldman L, Vassy J, et al. Systematic review: compar- ative effectiveness and safety of oral medications for type 2 diabetes meUitus. Ann Intern Med 2007 ; 147:386 - 399.

同被引文献47

  • 1郭剑,赵玉珠.二甲双胍治疗老年2型糖尿病患者中加用沙格列汀的临床效果观察[J].医学信息(医学与计算机应用),2014(15):451-451. 被引量:1
  • 2翟玉荣,刘波.黄芪多糖对糖尿病大鼠肾脏保护作用[J].遵义医学院学报,2007,30(3):243-244. 被引量:9
  • 3Green BD,Irwin N,Gault VA,et al. Development and ther-apeutic potential of incretin hormone analogues for type 2diabetes [J]. The British Journal of Diabetes and VascularDisease, 2005,5(3):134-140.
  • 4Tatosian DA,Guo Y,Schaeffer AK,et al. Dipeptidyl pep-tidase-4 inhibition in patients with type 2 diabetes treatedwith saxagliptin, sitagliptin, or vildagliptin[J]. Diabetes Ther-apy,2013,4(2) :431-442.
  • 5Defronzo RA,Hissa MN,Garber AJ,et al. The efficacy andsafety of saxagliptin when added to metformin therapy inpatients with inadequately controlled type 2 diabetes withmetformin alone[J]. Diabetes Care, 2009,32(9) : 1649-1655.
  • 6Goke B,Gallwitz B,Eriksson J,et al. Saxagliptin is non-inferior to glipizide in patients with type 2 diabetes mel-litus inadequately controlled on metformin alone:A 52-week randomised controlled trial[J]. International Journalof Clinical Practice,2010,64(12): 1619-1631.
  • 7Chacra AR, Tan GH, Apanovitch A , et al. Saxagliptinadded to a submaximal dose of sulphonylurea improvesglycaemic control compared with uptitration of sulphony-lurea in patients with type 2 diabetes : A randomised con-trolled trial [J]. International Journal of Clinical Practice,2009,63(9):1395-1406.
  • 8Goldman - Levine J D. Beyond metformin : initiating combination therapy in patients with type 2 diabees mellitus [ J ]. Pharmacotherapy,2011,31(s12) :s44 -s53.
  • 9American Diabetes Association. Standards of medical care-in diabetes - 2014 [ J]. Diabetes Care,2014,37 ( sl ) : 14 - 80.
  • 10中华医学会糖尿病学分会.中国2型糖尿病防治指南2013年版[M].北京:北京大学医学出版社,2013:19.

引证文献3

二级引证文献16

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部